Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Namwiwat Medical PCLBKK:NAM 39 EV-to-EBIT is 19.24 as of Aug. 17, 2026, which is 29% above its 10-year median of 14.95. GuruFocus rates BKK:NAM with a GF Score™ of 39/100 and a GF Value™ of ฿5.90 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Namwiwat Medical PCL ranks better than 50.11% on this metric.
The historical rank and industry rank for Namwiwat Medical PCL's EV-to-EBIT or its related term are showing as below:
BKK:NAM'
s EV-to-EBIT Range Over the Past 10 Years
Min: 8.14 Med: 14.95 Max: 60.06
Current: 19.24
During the past 6 years, the highest EV-to-EBIT of Namwiwat Medical PCL was 60.06. The lowest was 8.14. And the median was 14.95.
BKK:NAM's EV-to-EBIT is ranked better than 50.11% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 19.35
vs BKK:NAM: 19.24
Namwiwat Medical PCL (BKK:NAM) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Namwiwat Medical PCL's Enterprise Value for the quarter that ended in Mar. 2026 was ฿2,482 Mil.
Namwiwat Medical PCL's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿115 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Namwiwat Medical PCL EV-to-EBIT Related Terms
Namwiwat Medical PCL EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Namwiwat Medical PCL's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Namwiwat Medical PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Namwiwat Medical PCL EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Namwiwat Medical PCL's EV-to-EBIT falls into.
Namwiwat Medical PCL's current Enterprise Value is ฿2,216 Mil.
Namwiwat Medical PCL's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿115 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Namwiwat Medical PCL (BKK:NAM) has a EV-to-EBIT of 19.24 as of Aug. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Namwiwat Medical PCL and its competitors. This is 29% above median its historical median of 14.95. Over the past decade, Namwiwat Medical PCL's EV-to-EBIT has ranged from 8.14 to 60.06. According to the industry distribution chart, Namwiwat Medical PCL ranks #235 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 49.9%.
Is Namwiwat Medical PCL's EV-to-EBIT too high?
Namwiwat Medical PCL's current EV-to-EBIT of 19.24 is 29% above median its 10-year median of 14.95. Over the past 10 years, this metric has ranged from a low of 8.14 to a high of 60.06. The Medical Devices & Instruments industry median EV-to-EBIT is 19.35. Namwiwat Medical PCL's value of 19.24 is 0.6% below this industry median. Based on the distribution chart, Namwiwat Medical PCL ranks #235 out of 471 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Namwiwat Medical PCL has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Namwiwat Medical PCL ranks #235 out of 471 companies for EV-to-EBIT. This puts Namwiwat Medical PCL in the upper half of its industry. The industry median EV-to-EBIT is 19.35. Namwiwat Medical PCL's value of 19.24 is 0.6% below this benchmark. Historically, Namwiwat Medical PCL's own EV-to-EBIT has ranged from 8.14 to 60.06 over the past decade. While the company's 10-year median is 14.95 vs. the industry median of 19.35, Namwiwat Medical PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.35, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Namwiwat Medical PCL's current EV-to-EBIT of 19.24 is 0.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Namwiwat Medical PCL and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current EV-to-EBIT is 19.24, which is 29% above median its own 10-year median of 14.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿5.90, compared to a current price of ฿3.32 — trading 43.7% below its estimated fair value. The current EV-to-EBIT is 19.24, which is 29% above median its 10-year median of 14.95 and 0.6% below the Medical Devices & Instruments industry median of 19.35. Namwiwat Medical PCL's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current EV-to-EBIT is 19.24 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?
Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued.
The current stock price of ฿3.32 is trading 43.7% below its estimated GF Value™ of ฿5.90.
GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.
Key valuation signals for BKK:NAM:
EV-to-EBIT: 19.24 (29% above median its 10-year median of 14.95)
GF Value™: ฿5.90 vs. price of ฿3.32 (43.7% below fair value)
Industry Position: 0.6% below the Medical Devices & Instruments median (#235 of 471)
No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
39GF Score
Get the complete analysis for BKK:NAM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NAM has been successfully added to your 
